Active-ingredient Dossier
Bevacizumab
Active-ingredient Dossier for Bevacizumab (monoclonal antibody). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: MVASI
- Brand: VEGZELMA
- Brand: ONBEVZI
- Brand: BEVACIP
- Brand: ABEVMY
- Brand: ZIRABEV
- Therapeutic area: Oncology
What is
Bevacizumab Bevacizumab is a monoclonal antibody.
Australian brands containing
Bevacizumab — MVASI — VEGZELMA — ZIRABEV — ABEVMY — BEVACIP — ONBEVZI
Therapeutic areas
Bevacizumab is registered in oncology, with 6 brands containing this ingredient on the ARTG.
Sponsor landscape
Bevacizumab is marketed by six sponsors: Maxx Pharma, Aborns Pharmaceuticals, Amgen, Samsung Bioepis AU, Celltrion Healthcare, and Pfizer.
PBS and regulatory activity
One brand containing bevacizumab has PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2020-21 fiscal year, government expenditure on bevacizumab was approximately $90.3 million across 46,159 scripts. The latest PBAC outcome was recorded on 1 March 2025, with three brands having PBAC outcomes on record. The latest AusPAR was issued on 30 August 2023, with five brands having AusPARs on record.